GSK's Witty Calls Out Pricing as a Threat to EU Innovation
LONDON – Andrew Witty, CEO of GlaxoSmithKline plc and president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), hit out at austerity-driven pricing and reimbursement policies in an open letter to European heads of state delivered on Monday.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST